high definition diagnostics℠

Technology Designed to Reveal More

Simoa's revolutionary digital approach to immunoassays allows single molecules to be counted, delivering a roughly 1000-fold increase in sensitivity. This remarkable sensitivity combined with full automation unlocks a world of insight into disease detection, diagnosis, and patient treatment while meeting the demands of today's laboratory.


Unprecedented Sensitivity

1000 times greater sensitivity than conventional immunoassays.
Learn More.


Robust Multiplexing

Improve efficiencies and stretch samples with up to 10-plex assays.
Learn More.


Complete Automation

Sample in, result out with an intuitive, user-friendly interface.
Learn More.

Keep up with Kevin

Hear from our innovative thought leader, Kevin Hrusovsky, Quanterix' Executive Chairman, on Twitter (@KevinHrusovsky) and connect with him on LinkedIn for thought provoking commentary and insights as he discusses and shares ways to eradicate disease and promote personalized healthcare.


Trauma Test: Concussions in athletes

WHDH.com Boston Channel 7, reported by Joe Amorosino

Read the full article


Introducing Simoa 2.0

LEXINGTON, MA – October 28, 2015 Quanterix Corporation, a leader in high definition diagnostics, delivering ultrasensitive single molecule measurement for the benefit of human health, today announced the launch of Simoa 2.0, its next-generation ultrasensitive immunoassay platform. Simoa 2.0 addresses many customer requests and input collected during the rapid growth of Simoa’s first year and a half on the market, and includes numerous improvements to assay performance, hardware and software refinements and overall instrument usability. 

Read the Press Release

Quanterix in the News

Recent Publications